Company intelligence / Profile preview
Y-Biologics
Daejeon, South Koreaybiologics.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Successfully developed and licensed antibody technologies to Navigator Medicine in the US and Huadong Medicine in China. Co-developed IMB-101 (OXTIMA, a bispecific antibody targeting OX40L/TNF-α) and IMB-102 (a monoclonal antibody targeting OX40L) with partners.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Antibody drugsbispecific antibodiesmonoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
14 assets13 more assets in the full pipeline.
Request access →03
Partnerships
IMBiologicsHK inno.NNavigator MedicineHuadong MedicineLigaChem BioVaxCell BioUbix TherapeuticsGI Cell
Beyond the preview
Go deeper on Y-Biologics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Y-Biologics.